Alyssa Anderson
Family · Branford, CTNPI 1336421171
Payments from drug & device makers
Across 341 payments — averaging $17.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Regeneron Healthcare Solutions, Inc.$793
- Novo Nordisk$791
- AstraZeneca$653
- Pfizer$495
- Lilly USA, LLC$445
- plus $2K from 19 others
What the payments were for
- Food & beverage$5,85199%
- Education$481%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 78 | $1,178 |
| Regeneron Healthcare Solutions, Inc. | 32 | $793 |
| Novo Nordisk | 78 | $791 |
| AstraZeneca | 28 | $653 |
| Pfizer | 28 | $495 |
| Lilly USA, LLC | 21 | $445 |
| Amgen | 15 | $315 |
| GSK | 17 | $303 |
| Exact Sciences | 9 | $204 |
| Merck | 6 | $129 |
| Boehringer Ingelheim | 5 | $100 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $64 |
| Lucid Diagnostics Inc. | 3 | $62 |
| Dexcom, Inc. | 3 | $56 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $51 |
| Indivior Inc. | 2 | $50 |
| Xeris Pharmaceuticals, Inc. | 2 | $46 |
| Abbott | 1 | $24 |
| Alkermes, Inc. | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $22 |
| Ironwood Pharmaceuticals, Inc | 1 | $21 |
| Kowa Pharmaceuticals America, Inc. | 1 | $21 |
| Bayer | 1 | $19 |
| Johnson & Johnson | 1 | $18 |
| Seqirus USA Inc | 1 | $16 |
How this compares
$5,899 in reported general payments places this provider in the 90th percentile of 1,596 family providers in Connecticut.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 66 | $121,535 |
| EliquisApixaban | 18 | $24,668 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 11 | $4,181 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 23 | $2,278 |
| Levothyroxine Sodium | 97 | $2,258 |
| SynthroidLevothyroxine Sodium | 12 | $1,500 |
| Rosuvastatin Calcium | 157 | $1,442 |
| Atorvastatin Calcium | 211 | $1,322 |
| Losartan Potassium | 130 | $1,197 |
| Mirtazapine | 22 | $1,018 |
| Metoprolol Succinate | 73 | $1,012 |
| Amlodipine Besylate | 160 | $911 |
| Gabapentin | 44 | $794 |
| Lisinopril | 104 | $783 |
| Metformin Hcl | 96 | $719 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $791 | $121,53566 claims |
| PfizerEliquis | $495 | $24,66818 claims |
| Indivior Inc.Suboxone | $50 | $4,18111 claims |
| AbbVieSynthroid | $1,178 | $1,50012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,596 family providers in Connecticut.
Other family in Branford
- Elisha ChristiansonWaterbury$371K
- Kathryn TierneyNew Britain$140K
- Jennifer SilvaSouth Windsor$91K
- Carli WillardEnfield$74K
- Erin MartinMilford$70K
- Dayna GiordanoNew Haven$65K
- Diana BytyqiDerby$53K
- Farhiya AbdiSouth Windsor$30K
- Nicole SandilandsBridgeport$30K
- Ralph HirschfeldPutnam$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.